Caraco Pharmaceutical Laboratories, Ltd. v. Novo Nordisk A/S
179 L. Ed. 2d 653, 131 S. Ct. 1808, 563 U.S. 902, 2011 U.S. LEXIS 2434, 79 U.S.L.W. 3552
This text of 179 L. Ed. 2d 653 (Caraco Pharmaceutical Laboratories, Ltd. v. Novo Nordisk A/S) is published on Counsel Stack Legal Research, covering Supreme Court of the United States primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.
Bluebook
Caraco Pharmaceutical Laboratories, Ltd. v. Novo Nordisk A/S, 179 L. Ed. 2d 653, 131 S. Ct. 1808, 563 U.S. 902, 2011 U.S. LEXIS 2434, 79 U.S.L.W. 3552 (U.S. 2011).
Opinion
The Acting Solicitor General is invited to file a brief in this case expressing the views of the United States.
Free access — add to your briefcase to read the full text and ask questions with AI
Cite This Page — Counsel Stack
Bluebook (online)
179 L. Ed. 2d 653, 131 S. Ct. 1808, 563 U.S. 902, 2011 U.S. LEXIS 2434, 79 U.S.L.W. 3552, Counsel Stack Legal Research, https://law.counselstack.com/opinion/caraco-pharmaceutical-laboratories-ltd-v-novo-nordisk-as-scotus-2011.